AIM ImmunoTech (AIM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Nov, 2026Executive summary
Schedule 14A proxy materials filed by the registrant; filing indicates no fee required.
Voting matters and shareholder proposals
Annual meeting scheduled for Nov. 17, 2026; voting instructions requested by Nov. 16, 2026.
Voting options include ProxyVote, phone, or attending the meeting; materials are directed to holders as of Sep. 28, 2026.
Notice of Meeting, Proxy Statement, and Form 10-K are available for review before voting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AIM ImmunoTech
- Board recommends voting for all directors, auditor ratification, and executive pay approval.AIM
Proxy filing - Q2 2026 saw higher net loss, improved liquidity, and completed Phase 2 pancreatic cancer trial enrollment.AIMQ2 2026
- Ampligen delivers improved survival and safety in late-stage pancreatic cancer with ongoing clinical success.AIMCorporate presentation
- Board seeks approval for key share issuances and a reverse split to secure capital and compliance.AIMProxy filing
- Offering up to 13 million shares, the company targets pancreatic cancer but faces dilution and listing risks.AIMRegistration filing
- Approval of key share issuances and a reverse split is critical to future capital and compliance.AIMProxy filing
- Offering up to 31.3M shares via warrants, with dilution risk and a going concern warning.AIMRegistration filing
- Net loss improved to $3.0M as cash rose to $5.8M, but delisting risk remains due to low equity.AIMQ1 2026
- Ampligen’s phase II pancreatic cancer trial shows promise, with phase III planning and strong market potential.AIMVirtual Investor Closing Bell